XAIRHealthcare · Medical DevicesThe 2 Wall Street analysts covering Beyond Air, Inc. hold a median 12-month price target of $20 — +792.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Beyond Air, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on XAIR, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +792.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Sept 2026 | Lake Street | Initiates | Buy | $10 |
| 27 Mar 2026 | D. Boral Capital | Maintains | Buy | $10 |
| 27 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 18 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 10 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 21 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 11 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 July 2025 | D. Boral Capital | Initiates | Buy | — |
| 16 Aug 2024 | Roth MKM | Reinstates | Buy | $2.00 |
| 7 Aug 2024 | Piper Sandler | Maintains | Overweight | — |
| 25 June 2024 | BTIG | Downgrade | Neutral | — |
| 25 June 2024 | Piper Sandler | Maintains | Overweight | — |
| 30 Apr 2024 | Truist Securities | Maintains | Buy | — |
| 14 Nov 2023 | Truist Securities | Maintains | Buy | — |
| 28 July 2023 | Piper Sandler | Initiates | Overweight | — |
| 21 July 2023 | Truist Securities | Maintains | Buy | — |
| 23 June 2023 | Oppenheimer | Maintains | Outperform | — |
| 15 June 2023 | BTIG | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
XAIR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 88% of US stocks
Cheaper than 75% of US stocks
Cheaper than 67% of US stocks
Higher than 29% of US stocks
Higher than 37% of US stocks
Higher than 12% of US stocks
Higher than 9% of US stocks
Higher than 56% of US stocks
Higher than 3% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Beyond Air, Inc. has a market value of $2.2M and an enterprise value of $16.8M.
Revenue in the twelve months to 30 June 2026: $7.7M. The latest quarter grew 0.5% year on year.
Net income over the same four quarters: −$34.4M, a −447.6% net margin.
Diluted earnings per share, trailing twelve months: $−277.40.
Free cash flow in the twelve months to 30 June 2026: −$19.6M.
Trailing P/E: 0.0×; forward P/E: −1.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Beyond Air, Inc. employs 54 people — $142K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Beyond Air, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Beyond Air said it will report financial results for the quarter ended September 30, 2026, on Wednesday, November 11, 2026.
Why it matters — The announcement gives XAIR watchers the scheduled date for the company’s quarterly results.
Beyond Air reported preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026, its highest quarterly revenue, up about 30% sequentially and 27% year over year. The company attributed performance to continued adoption of first-generation LungFit PH, noted that its second-generation system remains under FDA review, and reaffirmed its 2026 and 2027 revenue guidance.
Why it matters — The update gives XAIR watchers a read on recent LungFit PH adoption and the company's reaffirmed revenue outlook, while the next-generation system remains under FDA review.
Beyond Air, Inc. announced that its management team will participate in the 2026 Cantor Global Healthcare Conference, scheduled for September 9-11, 2026, at the Waldorf Astoria New York. The company stated the news in a press release on September 2, 2026.
Why it matters — Conference participation gives XAIR watchers an opportunity to hear management discuss the company's nitric oxide-focused platform and strategy directly with investors.
Beyond Air, Inc. announced that the U.S. Food and Drug Administration granted Breakthrough Device Designation to its LungFit GO device for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD). The designation was announced on August 31, 2026.
Why it matters — The FDA Breakthrough Device Designation for LungFit GO may facilitate a faster regulatory review path for the company's nitric oxide-based treatment in a new indication, expanding Beyond Air's potential therapeutic applications.
Beyond Air, Inc. has entered into a definitive agreement to sell its NeuroNOS stake to UNIVO Pharmaceutical Industries. Upon closing, Beyond Air will receive shares representing 19.99% of UNIVO's issued and outstanding share capital, and is eligible to receive up to $32.5 million in development and commercial milestone payments.
Why it matters — XAIR watchers would track this divestiture as it changes Beyond Air's asset portfolio while providing the company potential equity in UNIVO and future milestone-based revenue from the NeuroNOS sale.
The 2 Wall Street analysts covering Beyond Air, Inc. have a median 12-month price target of $20, with estimates ranging from $10 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Beyond Air, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beyond Air, Inc. 42 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Beyond Air, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +792.9% from the last close, and Ticker Nerd's factor model ranks Beyond Air, Inc. 42 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Beyond Air, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XAIR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $30 over the next 12 months.
Beyond Air Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide-based therapies and delivery systems.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026". Beyond Air said it will report financial results for the quarter ended September 30, 2026, on Wednesday, November 11, 2026.
Beyond Air Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide-based therapies and delivery systems. The company’s core LungFit platform generates nitric oxide from ambient air and delivers it in a controlled way for respiratory care, with applications centered on neonatal respiratory conditions and other serious lung diseases. Beyond Air also operates development programs aimed at extending its nitric oxide technology across additional respiratory, neurological, and oncology-related uses. Its business is organized around Beyond Air, Beyond Cancer, and NeuroNos, reflecting a broader platform approach that combines device engineering with therapeutic development. Headquartered in Garden City, New York, Beyond Air serves the healthcare market through products and programs designed for hospital-based clinical use and specialized medical treatment settings.
CEO Mr. Robert Scott Goodman · 54 employees · United States · https://www.beyondair.net